Targeting B and T lymphocyte attenuator in cancer immunotherapy

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• B and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor homologous to CTLA-4 and PD-1.
• BTLA interacts with herpes virus entry mediator (HVEM), with overlapping binding sites allowing for competitive ligand/receptor interactions.
• BTLA's role in cancer immunotherapy is complex, potentially masking anti-PD-1 efficacy and promoting tumor growth via SHP-1 recruitment.

Purpose of the Study:

• To explore BTLA as a therapeutic target in cancer immunotherapy.
• To understand the dual role of BTLA in promoting immunosuppression and potentially stimulation.
• To identify strategies for targeting BTLA-HVEM interactions for anti-cancer effects.

Main Methods:

• Analysis of BTLA's structural homology with other co-inhibitory receptors.
• Investigation of ligand/receptor interactions at the BTLA-HVEM binding site.
• Exploration of signaling pathways (SHP-1, SHP-2, Grb2) associated with BTLA function.

Main Results:

• BTLA predominantly mediates an inhibitory, pro-tumor pathway by recruiting SHP-1.
• Targeting BTLA-HVEM ligation or using HVEM-blocking peptides are potential cancer immunotherapy strategies.
• Activation of Grb2 via BTLA's cytoplasmic tail suggests a potential stimulatory route that could enhance adoptive cell therapy.

Conclusions:

• BTLA represents a promising target in cancer immunotherapy due to its immunosuppressive functions.
• Understanding BTLA's complex signaling, including both inhibitory and potential stimulatory pathways, is crucial for effective therapeutic development.
• Strategies targeting BTLA-HVEM interactions and leveraging its stimulatory potential may improve responses to current immunotherapies like anti-PD-1 and adoptive cell therapy.